Eptinezumab (Vyepti) is a new CGRP monoclonal antibody for migraine prophylaxis that is administered by intravenous infusion. This article discusses its place in therapy, clinical trial efficacy and adverse effects.
Thorrun Govind is a community pharmacist, lawyer and former Chair of the Royal Pharmaceutical Society (RPS) English Pharmacy Board with extensive media experience in radio, television and social media. Here, she talks to Joy Ogden about how she is spreading the word about the value of pharmacists in the community as well as their further potential.
A range of novel lipid‐lowering agents are now available, providing options for patients unable to achieve sufficient control on older drugs such as statins. This article gives an overview of the main lipid‐lowering agents, their indications and usage, with a focus on the newer therapies targeting PCSK9.
What happens when people don’t know about an adverse drug event that landed them in hospital? This article uses a case of serotonin toxicity to illustrate the importance of communicating a patient's history of adverse effects to avoid the risk of re‐exposure and further harm.
Inclisiran (Leqvio) is a first‐in‐class cholesterol‐lowering small interfering RNA (siRNA) that works through gene silencing. Even though it has been approved by NICE and a population health agreement is in place, uptake in general practice has been slow. This article examines the barriers to uptake and how these could be addressed.
